1. Acknowledgement to Referees

   Acknowledgement to Referees Open access 06 December 2022 Pages: 1 - 2

2. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting

   • Conor McCloskey
   • María Toboso Ortega
   • Federico Manevy

   Systematic Review Open access 23 August 2022 Pages: 3 - 36

   

3. Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

   • F. Felizzi
   • Aino Launonen
   • P.-O. Thuresson

   Original Research Article Open access 28 July 2022 Pages: 37 - 46

   

4. Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

   • F. Felizzi
   • Aino Launonen
   • P.-O. Thuresson

   Correction Open access 12 September 2022 Pages: 47 - 48

5. Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia

   • Karan K. Shah
   • Melina Willson
   • Rachael L. Morton

   Original Research Article Open access 19 September 2022 Pages: 49 - 62

   

6. Correction to: Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia

   • Karan K. Shah
   • Melina Willson
   • Rachael L. Morton

   Correction Open access 31 October 2022 Pages: 63 - 63

7. Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study

   • Tetsuya Matsumoto
   • Akira Yuasa
   • Jason Gordon

   Original Research Article Open access 15 September 2022 Pages: 65 - 76

   

8. “Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England

   • Jiyeon Kang
   • John Cairns

   Original Research Article Open access 20 September 2022 Pages: 77 - 91

   

9. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis

   • Mehdi Javanbakht
   • Jesse Fishman
   • Amir Ansaripour

   Original Research Article Open access 14 September 2022 Pages: 93 - 110

   

10. Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia

    • Louisa G. Gordon
    • C. Wood
    • OPAL Study Group

    Original Research Article Open access 17 October 2022 Pages: 111 - 120

    

11. Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)

    • Meryl Brod
    • Michael Højby Rasmussen
    • Aristides Maniatis

    Original Research Article Open access 18 October 2022 Pages: 121 - 138

    

12. Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai Population

    • Krittaphas Kangwanrattanakul

    Original Research Article Open access 16 November 2022 Pages: 139 - 148

    

13. Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective

    • François-Xavier Chalet
    • Teodora Bujaroska
    • Andrew H. Briggs

    Original Research Article Open access 26 January 2023 Pages: 149 - 161